Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337770 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1PDK1DRD4DRD3 | |
| SCHEMBL6064721 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1PDK1DRD4DRD3 | |
| SCHEMBL1037760 | 0.79 | DRD4 (0.36) | PDK1CHEK1DRD4DRD3DRD2 | |
| SCHEMBL4190132 | 0.78 | GLA (0.41) | KDM4EALDH1A1PDK1DRD4DRD3 | |
| SCHEMBL29048494 | 0.78 | PDK1 (0.46) | PDK1DRD4DRD3DRD2 | |
| SCHEMBL4192102 | 0.77 | ALDH1A1 (0.39) | KDM4EALDH1A1PDK1DRD4DRD3 | |
| SCHEMBL5150493 | 0.77 | PDK1 (0.53) | KDM4EALDH1A1PDK1DRD4DRD2 | |
| SCHEMBL15925117 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1PDK1DRD4DRD3 | |
| SCHEMBL295933 | 0.77 | PDK1 (0.53) | KDM4EALDH1A1PDK1DRD4DRD2 | |
| SCHEMBL13355359 | 0.77 | CYP1A2 (0.41) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | KDM4E 524/4885ALDH1A1 3282/4885PDK1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.